Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
Condition(s):Non Small Cell Lung CancerLast Updated:February 21, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Non Small Cell Lung CancerLast Updated:February 21, 2023Terminated
Condition(s):ChondrosarcomaLast Updated:February 16, 2023Recruiting
Condition(s):Small Cell Lung CancerLast Updated:January 6, 2020Unknown status
Condition(s):Limited Stage Small Cell Lung Cancer; Not Progressed After First-line ChemoradiotherapyLast Updated:July 12, 2023Recruiting
Condition(s):Endometrial CancerLast Updated:November 8, 2019Unknown status
Condition(s):Hepatocellular Carcinoma; Thermal Ablation; Anlotinib; PDL-1Last Updated:March 4, 2021Unknown status
Condition(s):Malignant Brain Stem Tumor; GliomaLast Updated:December 16, 2020Unknown status
Condition(s):HepatocarcinomaLast Updated:April 5, 2022Unknown status
Condition(s):Esophageal Squamous Cell CarcinomaLast Updated:September 11, 2023Recruiting
Condition(s):Small Cell Lung Cancer RecurrentLast Updated:February 14, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.